4 assets in Leigh Syndrome

Therapeutic assets addressing Leigh Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Abi-009 Leigh Syndrome	Aadi Bioscience, Inc.	P2	CCC (53)
Mannitol Leigh Syndrome	Thiogenesis Therapeutics, Inc.	P2	CCC (53)
Sirolimus Leigh Syndrome	Matthew Demczko	P2	CCC (53)
Tti-0102: Cysteamine-Pantetheine Disulfide Leigh Syndrome	Thiogenesis Therapeutics, Inc.	P2	NR ()